AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

Recruiting

Phase 1

AB-101 & B-Cell Depleting mAbAB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

Sponsor:

Artiva Biotherapeutics, Inc.

Code:

NCT06265220

Conditions

Lupus Nephritis - WHO Class III

Lupus Nephritis - WHO Class IV

Refractory Systemic Lupus Erythematosus

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

AB-101

Cyclophosphamide

Fludarabine

Rituximab

Obinutuzumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-29. This information was provided to ClinicalTrials.gov by Artiva Biotherapeutics, Inc. on 2024-07-12.